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ABSTRACT
Background and objective Electronic health records
databases are increasingly used for identifying cohort
populations, covariates, or outcomes, but discerning
such clinical ‘phenotypes’ accurately is an ongoing
challenge. We developed a ﬂexible method using
overlapping (Venn diagram) queries. Here we describe
this approach to ﬁnd patients hospitalized with acute
congestive heart failure (CHF), a sampling strategy for
one-by-one ‘gold standard’ chart review, and calculation
of positive predictive value (PPV) and sensitivities, with
SEs, across different deﬁnitions.
Materials and methods We used retrospective
queries of hospitalizations (2002–2011) in the Indiana
Network for Patient Care with any CHF ICD-9 diagnoses,
a primary diagnosis, an echocardiogram performed,
a B-natriuretic peptide (BNP) drawn, or BNP >500 pg/mL.
We used a hybrid between proportional sampling by
Venn zone and over-sampling non-overlapping zones.
The acute CHF (presence/absence) outcome was based
on expert chart review using a priori criteria.
Results Among 79 091 hospitalizations, we reviewed
908. A query for any ICD-9 code for CHF had PPV
42.8% (SE 1.5%) for acute CHF and sensitivity 94.3%
(1.3%). Primary diagnosis of 428 and BNP >500 pg/mL
had PPV 90.4% (SE 2.4%) and sensitivity 28.8%
(1.1%). PPV was <10% when there was no
echocardiogram, no BNP, and no primary diagnosis.
‘False positive’ hospitalizations were for other heart
disease, lung disease, or other reasons.
Conclusions This novel method successfully allowed
ﬂexible application and validation of queries for patients
hospitalized with acute CHF.
BACKGROUND AND SIGNIFICANCE
Electronic health records (EHRs), including admin-
istrative claims and/or medical records databases,
are increasingly being used for identifying cohorts
with particular clinical characteristics, or ‘pheno-
types’. These cohort deﬁnitions play a role in
almost any retrospective analysis of EHR data, as
study population, covariate, or outcome. Their
greatest value may be realized if they can be devel-
oped, validated, and applied efﬁciently, in order to
accelerate the contribution of EHR data to com-
parative effectiveness and patient-centered out-
comes research. Phenotypes are required for
genetic association studies,1 2 drug safety surveil-
lance research,3–5 and quality of care measure-
ment.6–8
However, it takes time to develop phenotype
deﬁnitions, and then to discern how accurate,
useful, and transportable they are.8–11 The chal-
lenges derive from the inherent complexity and
uneven quality of real-world EHR data. The data
stored in an EHR are shaped by innumerable work-
ﬂows, interactions, and idiosyncrasies. As Hripcsak
and Albers point out, for phenotype development
and validation to someday reach a data-driven,
high-throughput state, ‘the physics of the medical
record’ will have to be much better understood.9
How have the data in the EHR been shaped? The
difﬁculties in answering that question—substantial
even in one EHR setting—are worse when multi-
source data are being used,12–15 as in a health infor-
mation exchange (HIE). An HIE receives varying
data from many institutions, each of which has its
own physics.
The ways that clinical phenotype populations are
deﬁned are being scrutinized, in systematic reviews
of the literature,16 17 through comparison of auto-
mated results with ‘chart reviews’ of medical
records,3 18 19 and through application of more
involved statistical techniques in drug safety surveil-
lance projects such as OMOP4 5 and FDA
Mini-Sentinel.3 18 Careful chart review methods
are still a mainstay, but the validation literature is
more complete for some conditions (myocardial
infarction) than for others (osteoporosis). The FDA
Mini-Sentinel initiative recently published methods
to help address the challenges of conducting such
chart reviews across multiple sites, in queries for
acute myocardial infarction.18 The Electronic
Medical Records and Genomics (eMERGE)
network described lessons learned in validating the
transportability of phenotypes across ﬁve leading
US EHRs.10 A related challenge is to distinguish an
acute exacerbation from the chronic presence of a
condition. Queries for vertebral compression frac-
tures had a high positive predictive value (PPV) in
identifying patients with a history of such fractures,
but it was much more challenging to speciﬁcally
identify new fractures.19
In a leading US HIE—the Indiana Network for
Patient Care (INPC)20—we developed a ﬂexible
method using overlapping (Venn diagram) queries
for shaping and validating phenotypes. Here we
describe this general approach, in the particular
‘use case’ to ﬁnd patients hospitalized with acute
congestive heart failure (CHF). We thus faced the
challenges of using multi-source HIE data, and of
discerning acute versus chronic illness. CHF, as a
prevalent and costly chronic disease, is an import-
ant clinical domain for EHR queries; electronic
data are actively being used in modeling CHF
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mortality, readmissions, and quality of care.21–27 Studying CHF
also affords the opportunity to use not only traditional billing-
type data like International Classiﬁcation of Diseases, Ninth
Revision (ICD-9) diagnosis codes but also clinical results like
echocardiograms and laboratory values (B-natriuretic peptide
(BNP)).28 29
We describe the development of the Venn diagram queries for
acute CHF hospitalizations, a corresponding sampling strategy
for one-by-one ‘gold standard’ chart review, and statistical
methods for calculating PPV and sensitivities, with SEs, across
different deﬁnitions. We submit that the advantage of this
approach is that we do not have to commit to a single set of
phenotype criteria at the outset. Rather, one set of chart reviews
can be used to validate multiple overlapping criteria for the
phenotype deﬁnition. Subsequent users of a phenotype query
may have various purposes—one size does not ﬁt all.
MATERIALS AND METHODS
Study design and data source
This was a retrospective study of hospitalizations (2002–2011)
in the INPC—a leading operational regional HIE. The INPC
was formed in 1994 by the Regenstrief Institute and the ﬁve
major hospital systems in Indianapolis. Its primary purpose is
for clinical data exchange, to improve the quality and efﬁciency
of healthcare; it is also used in research. Since 2009, the
number of hospital systems has expanded beyond the original
ﬁve. The INPC employs a master person index, which supports
integration of patient data across the different clinical and payer
institutions. The availability of data types—for example, diagno-
ses, procedures, pharmacy transactions, orders, imaging studies,
laboratory results, vital signs, and text reports (discharge sum-
maries, radiology reports, etc.)—varies by INPC institution.
Because chart review validation would be integral to this study,
we selected hospitalizations at two of the largest clinical institu-
tions in the INPC, where ample discharge summary report data
would be available for review. The study was approved by the
Institutional Review Board of Indiana University.
Inclusion and exclusion criteria
Hospitalizations at the two large clinical institutions were identi-
ﬁed, and data from those two institutions or from other institu-
tions including a large healthcare payer—between the dates of
hospital admission and discharge—were queried. To be included
in any of the phenotype deﬁnitions, we required that the patient
have had at least one ICD-9 diagnosis for CHF (428.xx, 402.
x1, 404.x1, 404.x3, or 398.91) during the hospital stay. To
evaluate the sensitivity of the phenotype deﬁnitions, we
assumed that patients hospitalized with acute CHF who were
missed by our inclusion criteria had a high BNP level; therefore,
we also queried for hospitalizations in which patients did not
have any ICD-9 diagnosis for CHF but did have a maximum
BNP >500 pg/mL. Children under age 18 were excluded.
Venn diagram criteria
In consultation with CHF-specialist cardiologists, and based in
part on considerations of what data from the INPC would be
feasible to analyze in a 1-year project, we selected several circles
for the Venn diagram. We made the distinction between the
presence of any ICD-9 code for CHF and ICD-9 code 428. We
also assessed whether or not the patient had a primary diagnosis
of CHF or of ICD-9 code 428. We added queries to delimit the
subsets of patients who had an echocardiogram performed
during the hospital stay, a BNP drawn during the hospital stay,
or a maximum BNP level >500 pg/mL. Complex criteria could
then be formed using ‘and’ and ‘or’ statements. To help generate
a sampling strategy for the ‘gold standard’ chart review, the
number of hospitalizations in each Venn diagram zone (ﬁgure 1)
was calculated.
Figure 2 shows the Venn diagram zones, each labeled with a
letter of the alphabet, to facilitate our reporting of results by dif-
ferent combinations of zones.
In planning for the sampling strategy, we did not consider
each Venn zone (or all possible combinations of the zones) to be
equally important, but rather focused on 10 sets that, a priori,
seemed as if they may have potential utility as phenotypes
(table 1).
Figure 1 Number of hospitalizations
by Venn diagram zone. BNP,
B-natriuretic peptide; CHF, congestive
heart failure.
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Sampling strategy
For the purpose of validation, our primary goal is to use manual
review of charts to estimate the prevalence of true cases (PPV)
and the sensitivity (proportion of all true cases identiﬁed) in a
Venn diagram region (combination of zones) deﬁned by an algo-
rithm. Since available resources generally do not permit manual
review of all cases identiﬁed by the various algorithms, a
random sample must be chosen from the population. To esti-
mate the prevalence of true positives in a given region, simple
random sampling in the region results in a larger variance of the
estimate compared to the variance that would arise from pro-
portional sampling (using the same proportion across each zone
within the region) with the same total sample size.30 For
example, to estimate the measures of accuracy of the algorithm
‘any dx of any CHF ICD-9 code’ (ﬁrst algorithm in table 1,
zones A-through-V in ﬁgure 2), proportional sampling of all the
zones is more efﬁcient than simple random sampling from the
entire large circle.
However, there are situations when we want to compare the
PPV or sensitivity of two different algorithms that are overlap-
ping, but one is not a strict subset of the other. For example, we
may be interested in comparing the algorithm of ‘primary diag-
nosis of ICD-9 code 428’ (zones L-through-Q in ﬁgure 2, and
row 5 in table 1) against the alternative of ‘primary diagnosis of
any CHF ICD-9 code and BNP >500 pg/mL’ (zones C,
J-through-M, in ﬁgure 2, and row 6 in table 1). The latter is less
restrictive in ICD-9 codes but more restrictive by the addition
of the BNP criterion. Since the overlapping region (zones L, M)
contributes to both algorithms, the non-overlapping regions—
(zones C, J, and K) and (zones N-through-Q)—are the source of
the differences in prevalence and sensitivity. To ensure adequate
power to detect such differences, we should sample a sufﬁcient
number of cases in all non-overlapping regions between pairs of
algorithms that may be compared. In the acute CHF example,
comparisons between all possible pairs of algorithms in table 1
could require estimates from these non-overlapping regions:
(A,B,C,D), (E,F), (G,H,I), ( J,K), (L), (M), (N through Q), (R),
(S,T) and (U,V). Therefore we need adequate sample sizes only
in these regions.
To optimize the sampling strategies for estimating PPVs and
to maximize power to detect differences in PPVs, we therefore
recommend a heuristic approach that is a compromise between
proportional sampling and over-sampling in the non-
overlapping regions to achieve adequate sample size. In the
acute CHF example, the total number of cases identiﬁed by any
set of criteria (any CHF ICD-9 code) is 66 942. We could
afford to perform manual reviews of no more than 1000 charts.
Therefore we started with an initial plan with a 1% sample
stratiﬁed on each zone, along with an increase in the sam-
pling proportion to 5% or 10% in the zones that made up
small regions so that the total sample size in each region at
least approached 100. On the other hand, a 1% sample in a
large zone yielded more than 100; manual reviews of that
many charts in a single region would provide diminishing
returns in terms of precision. Therefore, if resources were
limited during the chart review, we could reduce the sample
size in zone E.
Figure 2 Venn diagram zones. BNP,
B-natriuretic peptide; CHF, congestive
heart failure.
Table 1 Ten inclusion criteria sets, and corresponding zones of
the Venn diagram
Inclusion criteria Zones
Any dx of any CHF ICD-9 code (A-through-V)
Any dx of ICD-9 code 428 (E-through-V)
Any dx of any CHF ICD-9 code and any BNP
>500 pg/mL
(B, C, J, K, L, M, U, V)
10 dx of any CHF ICD-9 code (C, D, G-through-R)
10 dx of ICD-9 code 428 (L-through-Q)
10 dx of any CHF ICD-9 code, and BNP
>500 pg/mL
(C, J, K, L, M)
10 dx of ICD-9 code 428, and BNP >500 pg/mL (L, M)
10 dx of ICD-9 code 428, and BNP >500 pg/mL,
and Echo
L
10 dx of any CHF ICD-9 code, or BNP >500 pg/mL (B, C, D, G-through-Q, U, V)
10 dx of ICD-9 code 428, or BNP >500 pg/mL (B, C, J, K, L-through-Q, U, V)
BNP, B-natriuretic peptide; CHF, congestive heart failure.
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Chart reviews
In consultation with CHF-specialist cardiologists, we developed
a priori criteria and a questionnaire for the chart reviewers to
use in assessing whether acute CHF exacerbation was present or
absent during the hospital stay. The chart reviewers used
CareWeb (the clinician user-interface for the INPC) to review
free-text documents including hospital discharge summaries and
admission notes. A structured chart abstraction tool was used to
collect the data in Microsoft Access. The chart reviewers
included two of the authors (MBR, KN), supplemented by a
team of one other physician and four senior medical students.
The team was trained by the lead author, and cross-validation of
selected charts by the lead author was used to ensure consist-
ency; also, MBR and KN reviewed 67% of all charts. The
samples were divided such that at least two reviewers worked
on each Venn diagram zone.
The criteria for the presence or absence of acute CHF exacer-
bation included the treating physician’s assessment of why the
patient had been hospitalized, the Framingham criteria for acute
CHF,31 and/or whether a positive response to intravenous fur-
osemide had been documented. If acute CHF was judged not to
have been present, the reviewer noted whether or not chronic
CHF was a co-morbid illness, and also noted what the treating
physician(s) had documented as the reason for admission.
Statistical analyses
Estimation of PPV
In evaluating the performance of an algorithm for identifying a
phenotype, we do not use the measure speciﬁcity, which is
deﬁned as, among all true negatives, the proportion which the
algorithm labels as negative. This is because the overwhelming
number of hospitalizations in an EHR system is unrelated to a
particular phenotype, acute CHF in our example, so the speciﬁ-
city always approaches 1.0. Instead, the PPV is a meaningful
measure of how speciﬁc the algorithm is. PPV is deﬁned as,
among all cases identiﬁed by an algorithm, the proportion
which are true positives.
Let the mutually exclusive zones be labeled i=1, …, I, the
number of cases in zone i be Ni, with sampling proportion pi,
resulting in the number of cases sampled equal to ni=Nipi in zone i.
Out of the ni charts reviewed, let the number of true positives be
xi, which follows a binomial distribution with total ni and prob-
ability πi (the true proportion of true positive cases in zone i). For
any combination of zones i in a set Z as deﬁned by a given algo-
rithm, the overall PPV is estimated by: ðPieZ xi=piÞ=ð
P
ieZ NiÞ
with variance
P
ieZ (Ni=pi)pið1 piÞ
 
=ððPieZ NiÞ2Þ, the square
root of which gives the SE, in which (xi /ni) can be used as an esti-
mate of pi.
Estimation of sensitivity
An algorithm could have high PPV but could be so restrictive
that it misses the identiﬁcation of many true cases. Therefore we
also want to assess the performance of an algorithm by its sensi-
tivity, deﬁned as the proportion of all true cases that can be
identiﬁed by the algorithm. It is often not feasible to assess sen-
sitivity because we need to know the number of true cases
among the vast EHR system outside of the algorithm being con-
sidered; a reliable estimate for that number from a random
sample requires a huge sample. Validation studies that have
reported sensitivities generally have an independent list of
known true positives and estimate the sensitivity as the propor-
tion of the list that can be identiﬁed by the algorithm. If we had
previously performed a clinical study of hospitalized patients
evaluated for acute CHF, we would have had a list with which
to evaluate the sensitivities of our algorithms. Without such a
list, we assumed that any CHF hospitalizations not captured by
any of our algorithms had to have had BNP >500 pg/mL (zone
X in ﬁgure 2). We performed chart reviews on a sample of this
group to estimate the total number of true cases that escaped
identiﬁcation by any of our algorithms.
For an algorithm that corresponds to a region Z made up of
certain zones in the Venn diagram, the numerator of the sensi-
tivity is the estimated number of true positives in Z, given byP
ieZ xi=pi. The denominator, that is, the estimated number of
true positives in the entire EHR system, is common to all algo-
rithms, and is given by
P
ieY xi=pi, where Y denotes all zones
from which samples were drawn, including the zones outside of
all algorithms (zone X in our example). Thus the sensitivity
is given by {fPieZ xi=pig=f
P
ieY xi=pig. The approximate
variance from the delta process is given by:
ðN20=ðNoþN1Þ4Þ var (N1)þðN21=ðNoþN1Þ4Þ var (N0), where the
estimated numbers of true positives inside and outside the
region of an algorithm are, respectively, N0¼
P
i[Z Nipi,
N1¼
P
i[YnotZ Nipi, with respective variances var (N0)¼P
i[Z N
2
i pið1 piÞ=ni, and var(N1)¼
P
i[YnotZ N
2
i pið1 piÞ=ni.
Comparisons between algorithms
To test the PPV between any two algorithms, we simply take the
difference of the two estimated PPVs. The SE of the difference
estimate is given by the square root of the sum of their var-
iances. The equality of the two PPVs can also be tested using
the Z test formed by dividing the difference by its SE. The sen-
sitivities of two algorithms can be similarly compared.
RESULTS
At the two clinical institutions studied, we found 66 942 hospi-
talizations with at least one ICD-9 diagnosis for CHF; we also
found 12 149 hospitalizations with no ICD-9 diagnosis for
CHF but a maximum BNP level >500 pg/mL. We reviewed
charts for 810 of the 66 942, and 98 of the 12 149 hospitaliza-
tions. Table 2 shows the number of hospitalizations in each
Venn diagram zone, and the number sampled.
The results for the 10 queries of interest are shown in table 3.
A query for any ICD-9 code for CHF had PPV 42.8% (SE
1.5%) for acute CHF and sensitivity 94.3% (1.3%). A query for
a primary diagnosis of 428 and BNP >500 pg/mL had PPV
90.4% (SE 2.4%) and sensitivity 28.8% (1.1%).
When we examined other areas of the Venn diagram (particu-
lar zones, or combinations of zones not included in the 10
queries of interest above), the PPV varied widely. To cite one
example, in zone E (hospitalizations with an ICD-9 diagnosis of
428 which was not primary, and no echocardiogram, and no
BNP), the PPV was 8%.
Comparing ‘primary diagnosis of ICD-9 428’ with ‘primary
diagnosis of any CHF and BNP >500 pg/mL’, the latter algo-
rithm has higher PPV=(90.0–86.3%)=3.7%, with SE ofﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2:12 þ 2:52p ¼3:3%: A Z test (with Z-statistic of 3.7/3.3=1.1)
of the difference had p value >0.1, so the PPV of these two
algorithms did not differ signiﬁcantly. In contrast, the algorithm
‘primary diagnosis of ICD-9 428’ has signiﬁcantly higher
sensitivity by 14.1% (47.6%–33.5%) with SE ofﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1:72 þ 1:32p ¼2:1%, so it is a better choice than ‘primary diag-
nosis of any CHF and BNP >500 pg/mL’.
Two ellipses in the Venn diagram—(1) echocardiogram and
any diagnosis of 428, and (2) BNP level drawn and any diagno-
sis of 428—were not used, in and of themselves, as phenotype
queries (in tables 1 and 3). These two algorithms may be
348 Rosenman M, et al. J Am Med Inform Assoc 2014;21:345–352. doi:10.1136/amiajnl-2013-001942
Research and applications
 by guest on D
ecem
ber 22, 2016
http://jamia.oxfordjournals.org/
D
ow
nloaded from
 
valuable in a database composed exclusively of healthcare payer
claims; however, in this HIE with both clinical and payer data,
we focused our algorithm selection and sampling considerations
on BNP results (>500 pg/mL) and used the presence of an echo-
cardiogram as an ‘and’ statement in one of the algorithms. But
since the existence of a BNP result or echocardiogram may have
value in phenotype algorithms in healthcare payer databases, we
conducted a separate analysis of these two ellipses and their
intersection (table 4).
On chart review, ‘false positive’ hospitalizations were most
commonly for other heart disease (eg, coronary disease, arrhyth-
mia without acute CHF) or lung disease (eg, exacerbation of
chronic obstructive pulmonary disease (COPD), pneumonia).
However, as ﬁgure 3 shows, there was a wide range of other
reasons for admission.
As expected, the chart reviewers encountered hundreds of dif-
ferent ways that physicians had described the presence or
absence of acute CHF. Some of the turns of phrase were, from
true positive cases, ‘frank CHF’ or ‘profound diuresis’ (after fur-
osemide), and, from ‘false positive’ hospitalizations, ‘I doubt he
is in active heart failure at the moment’. We recognized various
false-positive clinical scenarios. The most salient involved
patients with ﬂuid overload because of renal failure. Some
patients had missed their scheduled dialysis session. Phrases like
‘missed dialysis’ or ‘dialysis catheter fell out’, while not disposi-
tive for the absence of acute CHF, seemed to have a negative
predictive value high enough to consider in our next project—
one involving the contribution that natural language processing
might make to our Venn diagram methods.
DISCUSSION
Developing and validating phenotypes in EHR data is time-
consuming. The eMERGE network recently underscored the
‘value of iterative algorithm development’, along with chart
review and calculation of PPV, when validating and ‘ﬁne-tuning’
a phenotype.10 We agree. We also submit that our Venn diagram
methods can—for at least some clinical phenotypes—increase
the efﬁciency of the work. The principal advantage is that we
do not have to commit to a single set of phenotype criteria at
the outset. Rather, one set of chart reviews can be used to valid-
ate multiple overlapping criteria. Subsequent users of the pheno-
type will have various purposes and may desire the ﬂexibility
conferred by having information about the test characteristics of
multiple overlapping options.
As clinical phenotypes take on many important roles in the
Big Data era ahead,32 we anticipate that it will be increasingly
important to estimate the sensitivity, not only the PPV. Our
methods enable derivation of point estimates and SEs of the sen-
sitivity, for the various overlapping queries, based on the
assumption that zone X in the Venn diagram contains all the
missed true cases. Without a ‘zone X’, sensitivity may be cost-
prohibitive to calculate. In a large EHR or HIE, to reliably esti-
mate the sensitivity by reviewing a random sample of all records
Table 3 Results for the 10 congestive heart failure (CHF) phenotype queries
Criteria to combine Venn diagram zones N in query Sensitivity (%) Sensitivity, SE (%) PPV (%) PPV, SE (%)
Any CHF 66 942 94.3 1.3 42.8 1.5
Any dx of 428 64 832 90.9 1.3 42.5 1.5
Any dx of CHF and BNP >500 pg/mL 21 801 50.8 1.8 70.7 2.5
10 dx of any CHF 19 339 54.8 1.9 86.0 2.2
10 dx of 428 16 724 47.6 1.7 86.3 2.5
10 dx of any CHF and BNP >500 pg/mL 11 298 33.5 1.3 90.0 2.1
10 dx of 428 and BNP >500 pg/mL 9662 28.8 1.1 90.4 2.4
10 dx of 428 and BNP >500 pg/mL and echocardiogram 5678 16.2 0.8 86.6 3.5
10 dx of any CHF or BNP >500 pg/mL 29 587 71.4 2.1 73.3 2.2
10 dx of 428 or BNP >500 pg/mL 28 863 69.6 2.1 73.2 2.2
High BNP, no ICD-9 diagnosis for CHF
Zone X: no ICD-9 dx of 428, but BNP >500 pg/mL 12 149 N/A N/A 14.3 3.5
BNP, B-natriuretic peptide; PPV, positive predictive value.
Table 2 Sampling numbers by Venn diagram zone
Venn zone
N in
zone
1%
sample
Target
sampling
proportion (%)
Goal N for
sampling
Actual N
sampled
A 846 9 5 42 32
B 351 4 5 18 15
C 531 6 5 27 19
D 382 4 5 19 19
E 16 999 170 1 170 134
F 7364 74 1 74 63
G 107 2 5 5 3
H 117 2 5 6 5
I 118 2 5 6 6
J 387 4 10 39 25
K 718 8 10 72 54
L 5678 57 2 114 97
M 3984 40 2 80 47
N 1425 14 1 14 9
O 2200 22 1 22 17
P 1639 16 1 16 17
Q 1798 18 1 18 18
R 255 3 10 26 21
S 6541 65 1 65 59
T 5350 54 1 54 49
U 4319 43 1 43 50
V 5833 58 1 58 51
All combined 66 942 669 988 810
High BNP, no ICD-9 diagnosis for CHF
X 12 149 N/A N/A 91 98
ICD-9 diagnosis for congestive heart failure (CHF) present.
BNP, B-natriuretic peptide.
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not identiﬁed by the phenotype query would require a huge
sample. But selecting a ‘zone X’ may be somewhat arbitrary and
may be sometimes impossible. In a similar study, we wrote a
phenotype query for outpatients with diabetic retinopathy;
ICD-9 diagnoses were readily available, but electronic elements
for a ‘zone X’ based on ophthalmology clinic data were not
available in the INPC.
In the acute CHF example presented here, the assumption
that ‘false negatives’ would always have a BNP >500 pg/mL is
of course a limitation. BNP itself is a parameter with its own
predictive relationship with acute CHF and may be affected by
body mass index, age, and kidney function.28 29 33 34 Because
some patients with BNP levels in the 100–500 pg/mL range
(and no CHF ICD-9 diagnosis) may have had acute CHF, our
reported sensitivities may be overestimates. However, only 14%
of the hospitalizations in zone X had acute CHF, even with the
strict >500 pg/mL threshold. Lowering the threshold to 100 pg/
mL would increase the number of hospitalizations in zone X
but would further lower the percentage there with acute CHF.
The validity of ICD-9 diagnosis-based queries for CHF varies
in previous studies. A review by Quach et al,35 of 25 administra-
tive data studies, found a wide range of PPV and sensitivities.
Goff et al,36 in a study of 5100 cardiac-related hospitalizations
(for myocardial infarction, coronary artery disease, dysrhyth-
mias, chest pain) from 1988–1994, found that CHF ICD-9
diagnoses had PPV 77% and sensitivity 67% for acute CHF.
The higher PPV and lower sensitivity than ours probably reﬂect
differences in the methods. The higher PPV makes sense in that
Goff ’s overall pool of hospitalizations was limited to
cardiac-related hospitalizations. The lower sensitivity may reﬂect
other etiologies of pulmonary edema (eg, renal) within the gold
standard. The ‘zone X’ equivalent in the Goff study—hospitali-
zations with no CHF ICD-9 code but any of a variety of other
heart-related ICD-9 codes—may have been more expansive than
ours. The Goff study predated the BNP era.37–40
More recently, Li et al,41 using linked Medicare and CHF/
myocardial infarction registry data, studied 13 queries with a nar-
rower range of CHF ICD-9 code deﬁnitions (and some with
diagnosis-and-medication criteria), with systolic dysfunction as
‘true positive’ (ejection fraction <45%). Not unexpectedly based
on these deﬁnitions, their PPVs were generally higher, and sensi-
tivities were lower, than ours. Our results based on ICD-9 codes
alone are perhaps closest to those of Schellenbaum et al, who, in
a study of incident CHF, compared CHF ICD-9 diagnoses
against adjudications made by a ﬁve-physician events committee;
among 1072 hospitalizations with a CHF ICD-9 diagnosis, the
ﬁve-physician events committee validated 575 (54%) as CHF.42
A query for acute CHF could be modiﬁed by applying add-
itional criteria. The chart reviews showed that some of the hospi-
talizations were for renal failure or for COPD. We reran the
automated queries to explore whether excluding hospitalizations
with an ICD-9 diagnosis for renal failure (584.xx, 585.xx, or
586.xx) or COPD (492.xx or 496.xx) might improve the PPVs
of the queries for acute CHF. The result was that the PPVs for
acute CHF were little changed. The PPVof the ‘any CHF’ query
was 39.8% when renal failure ICD-9 codes were excluded and
43.0% when COPD ICD-9 codes were excluded (versus 42.8%
without these exclusions). As with the ICD-9 codes for CHF, the
ICD-9 codes for renal failure and COPD are imprecise; more
sophisticated queries for these exclusion phenotypes will be
required. The Venn region where excluding renal failure ICD-9
codes made the biggest difference (an increase in PPV from
87.2% to 91.4%) was in (zones J, K)—that is, when there was a
high BNP and a primary diagnosis of one of the non-428.xx
CHF ICD-9 codes. That result makes sense, in that the non-428.
xx CHF ICD-9 codes include 404.x1 and 404.x3 (heart failure
with hypertensive heart and chronic kidney disease).
Figure 3 Reasons for admission
when it was not acute congestive
heart failure (CHF).
Table 4 Additional results (existence of BNP and/or
echocardiogram)
Criteria to combine
Venn diagram
zones
N in
query
Sensitivity
(%)
Sensitivity,
SE (%) PPV
PPV,
SE (%)
BNP exists and 428
exists
36 808 71.6 1.9 59.0 2.1
Echo exists and 428
exists
29 144 54.6 1.8 56.8 2.5
BNP exists and 428
exists and echo exists
20 034 45.0 1.7 68.2 3.0
BNP, B-natriuretic peptide; PPV, positive predictive value.
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Another query criterion one could explore is to specify the
hospital (or hospital system). We observed what appears to be a
substantial difference in the PPVs across the two clinical institu-
tions in this study. (When the phenotype was based on a query
for primary diagnosis of ICD-9 code 428, the absolute differ-
ence in PPV between the two institutions was 12.5%. When the
phenotype was based on a query for primary diagnosis of
ICD-9 code 428 and BNP >500 pg/mL, the absolute difference
in PPV between the two institutions was 8.6%.) This ﬁnding
reinforces our experience that phenotype queries vary in per-
formance across settings, based on differences in the quantity or
quality of data, the patient mix, the clinical workﬂows, or other
factors. Several studies from the eMERGE network illustrate the
transportability of phenotype algorithms across the (heteroge-
neous) eMERGE centers and the opportunities that having
multi-source data affords for retraining and reﬁning the algo-
rithms.10 11 43–45 A multi-institution regional HIE—even one
committed to standards for data and messaging—may encom-
pass even more heterogeneity than a network like eMERGE.
The Venn diagram and set theory methods may be useful in
studying the transportability of electronic phenotype queries
and in elucidating variation across institutions or cities.
Our approach has some additional limitations or nuances to
mention. There is not necessarily one clear choice of a ‘gold
standard’ for validation. In addition to the Framingham cri-
teria,31 there are others that we could have selected.46–50 As
seen in table 1, we did not quite always reach our chart review
sample goal in each zone; we had a short project timeline, and
assignments were divided among multiple team members. Still,
we adapted our assignments along the way to ensure reasonable
and balanced samples. Sometimes also, a detailed chart review
in a Venn diagram framework helps suggest ways that the pre-
ceding, automated phenotype queries could be improved. This
opportunity helped us revise and improve our queries in this
project.
We agree with Hripcsak and Albers that the ‘full challenge of
phenotyping is not broadly recognized’.9 In this project, we
reduced some complexity by using only two clinical institutions
for the hospitalizations in the INPC. The Venn diagram method
may have more value in future studies exploring a wider array
of HIE institutions. The ﬁrst time we used this method, to iden-
tify infantile hypertrophic pyloric stenosis,51 it was only by
comparing the non-overlap between ICD-9 code 750.5 (the
appropriate code for infants) and a non-ICD-9 circle that we
discovered that a hospital was coding some infants not with
750.5 but with a code for adults, 537.0 (acquired hypertrophic
pyloric stenosis). In the earliest stages of building a phenotype,
the Venn diagram can help reveal the ‘physics’9—or, in our con-
ception of it, the anthropology—of the EHR/HIE.
Acknowledgements We gratefully acknowledge Layla Baker, MBChB, MPH,
CCRP, for her assistance with the medical record reviews.
Contributors MR conceived and designed the study, analyzed and interpreted
data, drafted the article and revised it critically for important intellectual content,
and approved the ﬁnal version. JH helped conceive and design the study, revised the
article critically for important intellectual content, and approved the ﬁnal version. JM
conducted extensive electronic queries, analyzed and interpreted data, helped revise
the article for important intellectual content, and approved the ﬁnal version. KN
conducted extensive chart reviews with abstraction and interpretation of data,
helped revise the article for important intellectual content, and approved the ﬁnal
version. GE and KL helped conceive, design, and apply the statistical methods,
revised the article critically for important intellectual content, and approved the ﬁnal
version. IG-P helped conceive and design the study, revised the article critically for
important intellectual content, and approved the ﬁnal version. SLH helped conceive
the study, designed the statistical methods, analyzed and interpreted data, revised
the article critically for important intellectual content, and approved the ﬁnal version.
Funding This study was funded by Merck Sharp & Dohme.
Competing interests This study was funded by Merck Sharp & Dohme. JH is a
scientist employed by Merck Sharp & Dohme.
Ethics approval Indiana University Institutional Review Board.
Provenance and peer review Not commissioned; externally peer reviewed.
REFERENCES
1 Rice JP, Saccone NL, Rasmussen E. Deﬁnition of the phenotype. Adv Genet
2001:42:69–76.
2 Wojczynski MK, Tiwari HK. Deﬁntion of phenotype. Adv Genet 2008;60:75–105.
3 Cutrona SL, Toh S, Iyer, et al. Validation of acute myocardial infarction in the Food
and Drug Administration’s Mini-Sentinel program. Pharmacoepidemiol Drug Saf
2013;22:40–54.
4 Overhage JM, Ryan PB, Reich CG, et al. Validation of a common data model for
active safety surveillance research. J Am Med Inform Assoc 2012;19:54–60.
5 Stang PE, Ryan PB, Racoosin JA, et al. Advancing the science for active
surveillance: rationale and design for the Observational Medical Outcomes
Partnership. Ann Intern Med 2010;153:600–6.
6 National Quality Forum. Electronic Quality Measures (eMeasures). http://www.
qualityforum.org/Projects/e-g/eMeasures/Electronic_Quality_Measures.aspx.
(accessed Mar 2013).
7 National Committee for Quality Assurance. HEDIS and performance measurement.
http://www.ncqa.org/HEDISQualityMeasurement.aspx (accessed Mar 2013).
8 Kern LM, Malhotra S, Barrón Y, et al. Accuracy of electronically reported
‘meaningful use’ clinical quality measures. A cross-sectional study. Ann Intern Med
2013;158:77–83.
9 Hripcsak G, Albers DJ. Next-generation phenotyping of electronic health records.
J Am Med Inform Assoc 2013;20:117–21.
10 Newton KM, Peissig PL, Kho AN, et al. Validation of electronic medical
record-based phenotyping algorithms: results and lessons learned from the eMERGE
network. J Am Med Inform Assoc 2013;20:e147–54.
11 Carroll RJ, Thompson WK, Eyler AE, et al. Portability of an algorithm to identify
rheumatoid arthritis in electronic health records. J Am Med Inform Assoc 2012;19:
e162–9.
12 Kahn MG, Raebel MA, Glanz JM, et al. A pragmatic framework for single-site and
multisite data quality assessment in electronic health record-based clinical research.
Med Care 2012;50(Suppl):S21–9.
13 Desai JR, Wu P, Nichols GA, et al. Diabetes and asthma case identiﬁcation,
validation, and representativeness when using electronic health data to construct
registries for comparative effectiveness and epidemiologic research. Med Care
2012;50:S30–5.
14 Jollis JG, Ancukiewicz M, DeLong ER, et al. Discordance of databases designed for
claims payment versus clinical information systems. Implications for outcomes
research. Ann Intern Med 1993;119:844–50.
15 Tang PC, Ralston M, Arrigotti MF, et al. Comparison of methodologies for
calculating quality measures based on administrative data versus clinical data from
an electronic health record system: implications for performance measures. J Am
Med Inform Assoc 2007;14:10–15.
16 Jones N, Schneider G, Kachroo S, et al. A systematic review of validated methods
for identifying acute respiratory failure using administrative and claims data.
Pharmacoepidemiol Drug Saf 2012;21(Suppl 1):261–4.
17 Schneider G, Kachroo S, Jones N, et al. A systematic review of validated methods
for identifying hypersensitivity reactions other than anaphylaxis (fever, rash, and
lymphadenopathy), using administrative and claims data. Pharmacoepidemiol Drug
Saf 2012;21(Suppl 1):248–55.
18 Cutrona SL, Toh S, Iyer A, et al. Design for validation of acute myocardial infarction
cases in Mini-Sentinel. Pharmacoepidemiol Drug Saf 2012;21(Suppl 1):274–81.
19 Curtis JR, Mudano AS, Solomon DH, et al. Identiﬁcation and validation of vertebral
compression fractures using administrative claims data. Med Care 2009;47:69–72.
20 McDonald CJ, Overhage JM, Barnes M, et al. The Indiana Network for Patient Care:
a working local health information infrastructure. Health Affairs 2005;24:1214–20.
21 Render ML, Almenoff PL, Christianson A, et al. A hybrid Centers for Medicaid and
Medicare service mortality model in 3 diagnoses. Med Care 2012;50:520–6.
22 Joynt KE, Harris Y, Orav EJ, et al. Quality of care and patient outcomes in critical
access rural hospitals. JAMA 2011;306:45–52.
23 Muehlenbein CE, Hoverman JR, Gruschkus SK, et al. Evaluation of the reliability of
electronic medical record data in identifying comorbid conditions among patients
with advanced non-small cell lung cancer. J Cancer Epidemiol 2011;2011:983271.
24 Kottke TE, Baechler CJ. An algorithm that identiﬁes coronary and heart failure
events in the electronic health record. Prev Chronic Dis 2013;10:E29.
25 Amarasingham R, Moore BJ, Tabak YP, et al. An automated model to identify heart
failure patients at risk for 30-day readmission or death using electronic medical
record data. Med Care 2010;48:981–8.
26 Keyser DJ, Dembosky JW, Kmetik K, et al. Using health information
technology-related performance measures and tools to improve chronic care.
Jt Comm J Qual Patient Saf 2009;35:248–55.
Rosenman M, et al. J Am Med Inform Assoc 2014;21:345–352. doi:10.1136/amiajnl-2013-001942 351
Research and applications
 by guest on D
ecem
ber 22, 2016
http://jamia.oxfordjournals.org/
D
ow
nloaded from
 
27 American College of Cardiology Foundation (ACCF) American Heart Association
(AHA) Physician Consortium for Performance Improvement (PCPI™). Heart Failure
Performance Measurement Set. Updated 15 May 2012. http://www.ama-assn.org/
ama1/pub/upload/mm/pcpi/hfset-12-5.pdf (accessed Apr 2013).
28 Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type
natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med
2002;347:161–7.
29 Hainaut C, Gade W. The emerging roles of BNP and accelerated cardiac protocols in
emergency laboratory medicine. Clin Lab Sci 2003;16:166–79.
30 Scheaffer RL, Mendenhall W, Ott RL, et al. Elementary survey sampling. 7th edn.
Duxbury Resource Center, 2011.
31 McKee PA, Castelli WP, McNamara PM, et al. The natural history of congestive
heart failure: the Framingham study. N Engl J Med 1971;285:1441–6.
32 Murdoch TB, Detsky AS. The inevitable application of big data to health care. JAMA
2013;309:1351–2.
33 Ray P, Delerme S, Jourdain P, et al. Differential diagnosis of acute dyspnea: the value
of B natriuretic peptides in the emergency department. QJM 2008;101:831–43.
34 Januzzi JL Jr, Maisel AS, Silver M, et al. Natriuretic peptide testing for predicting
adverse events following heart failure hospitalization. Congest Heart Fail 2012;18:
S9–S13.
35 Quach S, Blais C, Quan H. Administrative data have high variation in validity for
recording heart failure. Can J Cardiol 2010;26:306–12.
36 Goff DC, Pandey DK, Chan FA, et al. Congestive heart failure in the United States:
Is there more than meets the I(CD code)? The Corpus Christi Heart Project. Arch
Intern Med 2000;160:197–202.
37 Valli N, Gobinet A, Bordenave L. Review of 10 years of the clinical use of brain
natriuretic peptide in cardiology. J Lab Clin Med 1999;134:437–44.
38 Mukoyama M, Nakao K, Saito Y, et al. Increased human brain natriuretic peptide in
congestive heart failure. N Engl J Med 1990;323:757–8.
39 Arad M, Elazar E, Shotan A, et al. Brain and atrial natriuretic peptides in patients
with ischemic heart disease with and without heart failure. Cardiology 1996;87:
12–7.
40 Grantham JA, Burnett JC. BNP: increasing importance in the pathophysiology and
diagnosis of congestive heart failure. Circulation 1997;96:388–90.
41 Li Q, Glynn RJ, Dreyer NA, et al. Validity of claims-based deﬁnitions of left
ventricular systolic dysfunction in Medicare patients. Pharmacoepidemiol Drug Saf
2011;20:700–8.
42 Schellenbaum GD, Heckbert SR, Smith NL, et al. Congestive heart failure incidence
and prognosis: case identiﬁcation using central adjudication versus hospital
discharge diagnoses. Ann Epidemiol 2006;16:115–22.
43 Kho AN, Hayes MG, Rasmussen-Torvik L, et al. Use of diverse electronic medical
record systems to identify genetic risk for type 2 diabetes within a genome-wide
association study. J Am Med Inform Assoc 2012;19:212–8.
44 Peissig PL, Rasmussen LV, Berg RL, et al. Importance of multi-modal approaches to
effectively identify cataract cases from electronic health records. J Am Med Inform
Assoc 2012;19:225–34.
45 Denny JC, Crawford DC, Ritchie MD, et al. Variants near FOXE1 are associated with
hypothyroidism and other thyroid conditions: using electronic medical records for
genome- and phenome-wide studies. Am J Hum Genet 2011;89:529–42.
46 Marantz PR, Tobin JN, Wassertheil-Smoller S, et al. The relationship between left
ventricular systolic function and congestive heart failure diagnosed by clinical
criteria. Circulation 1988;77:607–12.
47 Harlan WR, Oberman A, Grimm R, et al. Chronic congestive heart failure in
coronary artery disease: clinical criteria. Ann Intern Med 1977;86:133–8.
48 Carlson KJ, Lee DC, Goroll AH, et al. An analysis of physicians’ reasons for
prescribing long-term digitalis therapy in outpatients. J Chronic Dis 1985;38:733–9.
49 Schellenbaum GD, Rea TD, Heckbert SR, et al. Survival associated with two sets of
diagnostic criteria for congestive heart failure. Am J Epidemiol 2004;160:628–35.
50 Ives DG, Fitzpatrick AL, Bild DE, et al. Surveillance and ascertainment of
cardiovascular events: the Cardiovascular Health Study. Ann Epidemiol
1995;5:278–85.
51 Mahon BE, Rosenman MB, Kleiman MB. Maternal and infant use of erythromycin
and other macrolide antibiotics as risk factors for infantile hypertrophic pyloric
stenosis. J Pediatr 2001;139:380–4.
352 Rosenman M, et al. J Am Med Inform Assoc 2014;21:345–352. doi:10.1136/amiajnl-2013-001942
Research and applications
 by guest on D
ecem
ber 22, 2016
http://jamia.oxfordjournals.org/
D
ow
nloaded from
 
